
Opinion|Videos|January 31, 2025
Faricimab Molecular Design and Role of Ang-2
Panelists discuss how faricimab’s bispecific antibody design uniquely targets both VEGF-A and Ang-2 pathways, addressing the complementary role of Ang-2 in vascular destabilization and inflammation in retinal diseases.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What is the unique nature of the faricimab molecule, and what is the clinical rationale for targeting Ang-2 in treating retinal diseases?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The gene therapy shift: A closer look at the science powering next-generation retinal treatments
2
How European clinicians are revolutionizing retina care
3
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
4
FLORetina 2025: Mary Elizabeth Hartnett on ROP research and risk management
5









































